Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical-stage drug discovery company Siena Biotech has retained Proteome Sciences as preferred supplier of protein and peptide biomarker services for the company's drug development programs, under a master research agreement (MRA).
Subscribe to our email newsletter
The agreement allows Proteome to apply its PS Biomarker Services to deliver an elaborated analysis of post-translational modifications on a neurological disease-related protein
Proteome is also expected to apply proprietary sample preparation and analytical methods blended with Orbitrap Velos mass spectrometry to deliver PTM map of Siena Biotech’s protein target.
Siena Pharmacology head Andrea Caricasole said Proteome Sciences will perform mass spectrometry analysis on proteins of interest to Siena Biotech.
Proteome CEO Christopher Pearce said in addition, using Tandem Mass Tags they can develop targeted mass spectrometry assays for implementation in clinical trials and routine clinical medicine.